Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03527966 · ClinicalTrials.gov registry record · Phase 4
rhBMP-2 Versus Vivigen in Lumbar Fusion Procedures
A Phase 4 study, sponsored by Virtua Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT03527966: Clinical Trial Phase 4 study, sponsored by Virtua Health.
NCT03527966 is a Phase 4 study that was terminated before completion, run by Virtua Health. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03527966, a Phase 4 study, was terminated before completion, sponsored by Virtua Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study is aimed at comparing the overall efficacy (clinical and radiographic) of Vivigen, a novel cellular allograft product, and rhBMP-2 when utilized in lumbar fusion procedures.
Primary Outcome
The ODI is one of the most commonly utilized condition-specific measures of disability used in the management of spinal disorders (0-no disability, to 100-maximum disability possible)
Interventions
- BIOLOGICAL 5cc Vivigen and local autograft
- BIOLOGICAL Small kit rhBMP-2 with local autograft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-07-03 |
| Est. Completion | 2018-07-27 |
| Phase | Phase 4 |
Why NCT03527966 stopped before completion
NCT03527966 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which 5cc Vivigen and local autograft is the first listed.
NCT03527966 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03527966 about?
NCT03527966 is a clinical study titled "rhBMP-2 Versus Vivigen in Lumbar Fusion Procedures". This study is aimed at comparing the overall efficacy (clinical and radiographic) of Vivigen, a novel cellular allograft product, and rhBMP-2 when utilized in lumbar fusion procedures.
What is the current status of trial NCT03527966?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2017-07-03. Estimated completion is 2018-07-27.
What interventions are being tested in trial NCT03527966?
The interventions under investigation include: 5cc Vivigen and local autograft (BIOLOGICAL), Small kit rhBMP-2 with local autograft (BIOLOGICAL).
Who is sponsoring clinical trial NCT03527966?
This trial is sponsored by Virtua Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03527966's enrollment target sits among peer trials
3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI